Get the Stockscreener App
68.25
0.70%
-0.48
Biomarin Pharmaceutical Inc stock is traded at $68.25, with a volume of 2.24M.
It is down -0.70% in the last 24 hours and up +9.15% over the past month.
See More
Previous Close:
$68.73
Open:
$68.77
24h Volume:
2.24M
Relative Volume:
1.51
Market Cap:
$12.70B
Revenue:
$2.75B
Net Income/Loss:
$322.29M
P/E Ratio:
40.87
EPS:
1.67
Net Cash Flow:
$300.88M
1W Performance:
+5.24%
1M Performance:
+9.15%
6M Performance:
-26.27%
1Y Performance:
-22.92%
1-Day Range:
$67.76
$70.26
1-Week Range:
$64.35
$70.50
52-Week Range:
$60.63
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
68.25 | 12.70B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up on Strong Earnings - MarketBeat
Cantor Fitzgerald Reiterates Overweight Rating for BioMarin Pharmaceutical (NASDAQ:BMRN) - MarketBeat
UBS Group Boosts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $113.00 - MarketBeat
Piper Sandler Raises BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $126.00 - MarketBeat
BioMarin to Report Q4 Earnings: Here's What to Expect - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $103.00 at Bank of America - MarketBeat
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Simply Wall St
Zacks Research Issues Positive Estimate for BMRN Earnings - MarketBeat
Pfizer stops commercialization of hemophilia gene therapy Beqvez - Reuters
58,400 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by Alberta Investment Management Corp - MarketBeat
Cantor Fitzgerald maintains BioMarin stock with $90 target By Investing.com - Investing.com South Africa
BioMarin’s Earnings Call Highlights Strong Growth and Optimism - TipRanks
BioMarin’s Voxzogo Expected To Benefit From ‘Sticky’ Nature Of Achondroplasia Market - Scrip
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today - Yahoo
BioMarin Pharmaceutical (NASDAQ:BMRN) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2025 Earnings Guidance - MarketBeat
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews - Benzinga
BioMarin Earnings: Sales Driven by Strong Uptake of Voxzogo and Enzyme Therapies; Shares Undervalued - Morningstar
BioMarin's Narrow Moat Supported by Rare Disease Therapies and Developing Pipeline - Morningstar
Cantor Fitzgerald maintains BioMarin stock with $90 target - Investing.com
UBS Adjusts Price Target on BioMarin Pharmaceutical to $113 From $109, Maintains Buy Rating - Marketscreener.com
Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View - Yahoo Finance
BMO maintains $115 target on BioMarin stock, cites growth potential - Investing.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2024 Earnings Call Transcript - MSN
Piper Sandler lifts BioMarin stock target to $126, maintains Overweight - Investing.com
Zacks Research Analysts Boost Earnings Estimates for BMRN - MarketBeat
Roku, BioMarin, Amplitude - TradingView
BioMarin projects 10% revenue growth to $3.1B-$3.2B for 2025, driven by VOXZOGO expansion - MSN
BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Thursday - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by New York State Teachers Retirement System - MarketBeat
BioMarin’s Record Growth and 2025 Outlook - TipRanks
After-hours movers: Carvana, Klaviyo, NerdWallet, BioMarin Pharma, and more - Investing.com
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue Estimates - Nasdaq
BioMarin: EPS Surges Past Expectations - The Motley Fool
BioMarin Pharma Expects Double-Digit Revenue And Profitability Growth In 2025 - Nasdaq
BioMarin: Q4 Earnings Snapshot - The Bakersfield Californian
BioMarin Pharmaceutical Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set -- Shares Up After Hours - Marketscreener.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars - Financial Content
BioMarin Pharmaceutical Inc. Reports Fourth Quarter and Full Year 2024 Results - TradingView
Biomarin Pharma earnings beat by $0.37, revenue topped estimates - Investing.com Canada
Earnings Flash (BMRN) Biomarin Pharmaceutical Posts Q4 Revenue $747M, vs. FactSet Est of $712.3M - Marketscreener.com
Biomarin Pharmaceutical Inc. Q4 Profit Increases, Beats Estimates - Nasdaq
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Cut by Van ECK Associates Corp - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Rhumbline Advisers Buys 11,025 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings - The Globe and Mail
Savant Capital LLC Acquires 14,930 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? - Yahoo Finance
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):